In the last UK election in 2019, the NHS emerged as a major talking point, as the scale of the country’s support of the service was brought to the fore.
On Wednesday 13th September, pharmaphorum headed to London’s Wellcome Collection for Gilead’s book launch of “From the Margins”, a unique and impactful publication that brings together in o
If NICE is to remain a “beacon of evidence-based medicine”, it must become more agile, more flexible, and more ready to adapt – and COVID-19 has proved that it is more than capable of doing
COVID-19 has laid the UK’s health inequalities bare and created an imperative for the NHS to develop a step-change in how it cares for diverse and marginalised communities.
Health inequalities are a long-term condition and inclusive research is the only disease modifying therapy in the pipeline – but how can the community drive practical change?
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.<